Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance ...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced that Laura J. Esserman, MD ...
mskcc.org

What Is Invasive Lobular Carcinoma? MSK Doctors Explain

The leaders of the MSK Lobular Breast Cancer program (from left), breast pathologist Fresia Pareja, MD, PhD; breast surgeon Anita Mamtani, MD; breast medical oncologist Sherry Shen, MD. The program is ...
ascopubs.org

Temporal trends in active surveillance and treatment strategies for low-risk, hormone receptor-positive ductal carcinoma in situ in the US.

Assessing satisfaction for participants in a statewide cancer drug repository network. This is an ASCO Meeting Abstract from the 2025 ASCO Quality Care Symposium. This abstract does not include a full ...
Hosted on MSN

AI’s Expanding Role in Medicine: How Artificial Intelligence Is Helping Doctors Detect Cancer Earlier

*Artificial intelligence is rapidly transforming how doctors identify disease, with cancer diagnostics at the forefront of this medical revolution. For millions of patients, AI now provides a crucial ...